Sanofi (EPA:SAN) received a €82.00 ($101.23) target price from analysts at Sanford C. Bernstein in a note issued to investors on Wednesday. The brokerage currently has a “neutral” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 25.98% from the stock’s current price.

Several other equities analysts have also commented on SAN. Goldman Sachs Group set a €82.00 ($101.23) price target on Sanofi and gave the stock a “neutral” rating in a research report on Wednesday. Deutsche Bank set a €93.00 ($114.81) price target on Sanofi and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Berenberg Bank set a €97.00 ($119.75) price target on Sanofi and gave the stock a “neutral” rating in a research report on Wednesday. Kepler Capital Markets set a €83.00 ($102.47) price target on Sanofi and gave the stock a “buy” rating in a research report on Tuesday. Finally, UBS Group set a €82.00 ($101.23) price target on Sanofi and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of €84.63 ($104.48).

Sanofi (EPA:SAN) opened at €65.09 ($80.36) on Wednesday. The company has a market capitalization of $82,220.00 and a P/E ratio of 21.55. Sanofi has a 52-week low of €64.74 ($79.93) and a 52-week high of €92.97 ($114.78).

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/08/sanofi-san-pt-set-at-82-00-by-sanford-c-bernstein.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.